123 related articles for article (PubMed ID: 33238616)
1. Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression.
Warburton L; Calapre L; Pereira MR; Reid A; Robinson C; Amanuel B; Ziman M; Millward M; Gray E
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33238616
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup.
Rubatto M; Fava P; Stanganelli I; Ribero S; Pigozzo J; Di Giacomo AM; Ridolfi L; Tronconi MC; Trojaniello C; Bersanelli M; Garutti M; Indini A; De Risi I; De Tursi M; Merelli B; Morgese F; Occelli M; Cappellini GCA; Poletto S; Fedele D; Brugnara S; Frisinghelli M; Formisano L; Conca R; Tucci M; Russillo M; Ceroni L; Queirolo P; Targato G; Strippoli S; Mandalà M; Guida M; Quaglino P
Eur J Cancer; 2023 Jul; 187():25-35. PubMed ID: 37099946
[TBL] [Abstract][Full Text] [Related]
3. Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients.
Warburton L; Reid A; Amanuel B; Calapre L; Millward M; Gray E
Front Oncol; 2023; 13():1280730. PubMed ID: 38179171
[TBL] [Abstract][Full Text] [Related]
4. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.
Lee JH; Long GV; Menzies AM; Lo S; Guminski A; Whitbourne K; Peranec M; Scolyer R; Kefford RF; Rizos H; Carlino MS
JAMA Oncol; 2018 May; 4(5):717-721. PubMed ID: 29423503
[TBL] [Abstract][Full Text] [Related]
5. The dynamics of circulating tumour DNA (ctDNA) during treatment reflects tumour response in advanced melanoma patients.
Di Nardo L; Del Regno L; Di Stefani A; Mannino M; Fossati B; Catapano S; Quattrini L; Pellegrini C; Cortellini A; Parisi A; Capoluongo E; Autilio C; Fargnoli MC; Peris K
Exp Dermatol; 2023 Oct; 32(10):1785-1793. PubMed ID: 37533342
[TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study.
Herbreteau G; Vallée A; Knol AC; Théoleyre S; Quéreux G; Varey E; Khammari A; Dréno B; Denis MG
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33920470
[TBL] [Abstract][Full Text] [Related]
7. Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy.
Herbreteau G; Vallée A; Knol AC; Théoleyre S; Quéreux G; Varey E; Khammari A; Dréno B; Denis MG
Oncotarget; 2018 May; 9(38):25265-25276. PubMed ID: 29861869
[TBL] [Abstract][Full Text] [Related]
8. Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
Seremet T; Planken S; Schreuer M; Jansen Y; Delaunoy M; El Housni H; Lienard D; Del Marmol V; Heimann P; Neyns B
Melanoma Res; 2018 Feb; 28(1):65-70. PubMed ID: 29227333
[TBL] [Abstract][Full Text] [Related]
9. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.
Wang Z; Cheng Y; An T; Gao H; Wang K; Zhou Q; Hu Y; Song Y; Ding C; Peng F; Liang L; Hu Y; Huang C; Zhou C; Shi Y; Zhang L; Ye X; Zhang M; Chuai S; Zhu G; Hu J; Wu YL; Wang J
Lancet Respir Med; 2018 Sep; 6(9):681-690. PubMed ID: 30017884
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors.
Pedersen JG; Madsen AT; Gammelgaard KR; Aggerholm-Pedersen N; Sørensen BS; Øllegaard TH; Jakobsen MR
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32486146
[TBL] [Abstract][Full Text] [Related]
11. The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies-Beyond
Marsavela G; Johansson PA; Pereira MR; McEvoy AC; Reid AL; Robinson C; Warburton L; Khattak MA; Meniawy TM; Amanuel B; Millward M; Hayward NK; Ziman MR; Gray ES; Calapre L
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33339135
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
Anagnostou V; Forde PM; White JR; Niknafs N; Hruban C; Naidoo J; Marrone K; Sivakumar IKA; Bruhm DC; Rosner S; Phallen J; Leal A; Adleff V; Smith KN; Cottrell TR; Rhymee L; Palsgrove DN; Hann CL; Levy B; Feliciano J; Georgiades C; Verde F; Illei P; Li QK; Gabrielson E; Brock MV; Isbell JM; Sauter JL; Taube J; Scharpf RB; Karchin R; Pardoll DM; Chaft JE; Hellmann MD; Brahmer JR; Velculescu VE
Cancer Res; 2019 Mar; 79(6):1214-1225. PubMed ID: 30541742
[TBL] [Abstract][Full Text] [Related]
13. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
14. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
15. Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy.
Keller L; Guibert N; Casanova A; Brayer S; Farella M; Delaunay M; Gilhodes J; Martin E; Balagué G; Favre G; Pradines A; Meyer N
Acta Derm Venereol; 2019 Feb; 99(2):206-210. PubMed ID: 30393817
[TBL] [Abstract][Full Text] [Related]
16. Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma.
Manson G; Brice P; Herbaux C; Silva MG; Bouabdallah K; Deau B; Bouteloup J; Schiano JM; Nicolas-Virelizier E; Maerevoet M; Ghesquieres H; Stamatoullas A; Antier C; Carlo-Stella C; de Charette M; Poizeau F; Dercle L; Houot R
Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):1144-1153. PubMed ID: 32860075
[TBL] [Abstract][Full Text] [Related]
17. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
18. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
[TBL] [Abstract][Full Text] [Related]
19. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
Ashida A; Sakaizawa K; Uhara H; Okuyama R
Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
[TBL] [Abstract][Full Text] [Related]
20. Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.
Hogan SA; Courtier A; Cheng PF; Jaberg-Bentele NF; Goldinger SM; Manuel M; Perez S; Plantier N; Mouret JF; Nguyen-Kim TDL; Raaijmakers MIG; Kvistborg P; Pasqual N; Haanen JBAG; Dummer R; Levesque MP
Cancer Immunol Res; 2019 Jan; 7(1):77-85. PubMed ID: 30425105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
